Dott.ssa Giandini Carlotta

Medico

Contatti

Mail: carlotta.giandini@istitutotumori.mi.it
Tel: 0223902480

Specialità / Dipartimento

Radioterapia

Mi sono diplomata in Radioterapia presso l'Università Statale di Milano con tesi dal titolo: “Volumetric Modulated Arc Therapy (VMAT) versus Intensity Modulated Proton Therapy (IMPT) for left sided breast cancer: Dosimetric and Normal Tissue Complication Probability (NTCP) evaluation of a hypofractionated regimen (HypoRT)”.

Attualmente, in qualità di giovane radioterapista, svolgo la mia attività clinica come collaboratrice professionale presso la S.C. di Radioterpia di questa Fondazione. Mi occupo principalmente del trattamento del carcinoma mammario in tutti i suoi stadi, compresi i pazienti con patologia oligo e polimetastatica, con particolare attenzione al distretto del sistema nervoso.

Collaboro quotidianamente in setting multidisciplinare con i colleghi Senologi ed Oncologi medici.
Partecipo attivamente come investigator a trial clinici sulla patologia mammaria mono e multicentrici, osservazionali e randomizzati.
Sono co-autrice di pubblicazioni cliniche sulla patologia mammaria edite su riviste nazionali ed internazionali.

Elenco pubblicazioni Orcid

• “DECIDE STUDY”: “Development and Validation of Multiparametric Radiomics Models: Characterization of the Breast Parenchyma and Prediction of the Tumor Molecular Profile” Alleanza contro il Cancro.

• “EUROPA TRIAL”: Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer.

• “PRISCILLA TRIAL”: Partial Radiotherapy for breast in situ carcinoma of intermediate low risk al local adjuvant treatment.

• “TAORMINA TRIAL”: Treatment of oligometastatic breast cancer-a randomized phase 3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1st line treatment.

• “FASTPG01”: Radioterapia adiuvante ipofrazionata secondo schema ultra-ipofrazionato dopo chirurgia conservativa in pazienti affette da neoplasia della mammella.
• “RECARE”

• “RAPID SOLUTION”. Optimizing Radiotherapy Planning: An AI-Driven Solution for Breath Hold Selection in Breast Cancer. Founded by Fondazione IRCCS Istituto Nazionale dei Tumori-Valorizzazione delle Ricerca Fondi 5per1000, 2025-2026.

• “TETRIS” Risk assessment Tools for severe side Effects after breasT
Radiotherapy: radiation safety through biological extended models and dIgital twinS. HORIZON-EURATOM, 2024-2027.

• “Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors. REQUITE”. Funded by European Union’s 7th Framework Programme for research, technological development and demonstration, 2013-2018.

• “RAD-PRECISE”: Personalized radiotherapy: incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicity”. Funded by “Joint transnational call for proposals (2018) for research projects on personalized medicine – smart combination of pre-clinical and clinical research with data and ICT solutions”, ERAPerMed, 2019-2022

• “Mechanistic computational modelling of radiation damage to microvasculature and of its effect on tumor microenvironment”. Funded by AIRC, 2019-2024.

• “ROSANNA PROJECT”: cardiotoxicity in young breast cancer patients. Funded by AIRC, 2021-2026.

• “PNNR-POC-2023-12378113” A Composite Assay for HER2-Positive Early-Stage Breast Cancer Management. Funded by PNNR 2024-2027